Related Experiment Video
Updated: Dec 30, 2025
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Vaccine development for capsulate bacteria causing pneumonia
Fiona Mary Russell1, Jim Buttery
1Centre for International Child Health, and Murdoch Childrens Research Institute, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Parkville, Melbourne, Australia.
Insights
Pneumonia significantly impacts children and the elderly, with Streptococcus pneumoniae and Haemophilus influenzae type b being leading bacterial causes in children. Vaccines show promise, but further development is needed for widespread protection against pneumonia.
Area of Science:
- Pediatrics
- Infectious Diseases
- Epidemiology
Background:
- Pneumonia disproportionately affects children and the elderly, leading to significant mortality and disability globally.
- Epidemiologic data on pneumonia incidence and causative agents remain limited.
- Key bacterial pathogens include Streptococcus pneumoniae (SP), Haemophilus influenzae type b (Hib), and Group B Streptococcus (GBS).
Purpose of the Study:
- To review the epidemiology of pneumonia, focusing on causative organisms and the impact of vaccines.
- To highlight the role of Streptococcus pneumoniae, Haemophilus influenzae type b, and Group B Streptococcus in pediatric pneumonia.
- To discuss the efficacy and limitations of current and developing vaccines.
Main Methods:
- Literature review of epidemiologic data on pneumonia.
- Analysis of causative agents in different age groups, particularly neonates and children.
- Evaluation of vaccine efficacy and impact on disease incidence.
Main Results:
- Streptococcus pneumoniae is the primary cause of bacterial pneumonia in children beyond the neonatal period.
- Haemophilus influenzae type b and Streptococcus pneumoniae are leading causes in childhood; Hib vaccines prevent pneumonia in developing nations.
- Group B Streptococcus remains a significant cause of neonatal sepsis and pneumonia.
- SP conjugate vaccines show efficacy in low-incidence areas but offer marginal protection in high-incidence populations.
- Non-vaccine SP serotypes have increased carriage but not invasive disease post-vaccination.
- Group B Streptococcus vaccines are in early clinical development.
Conclusions:
- Pneumonia remains a major global health challenge, especially for young children and the elderly.
- Vaccination strategies, including Hib and SP conjugate vaccines, have impacted pneumonia incidence, though challenges remain.
- Further development of vaccines, particularly for Group B Streptococcus, is crucial for reducing the burden of pneumonia.
Abstract:
Pneumonia strikes the extremes of the age spectrum, causing maximal death and disability in children and the elderly. Despite its worldwide impact, there is a paucity of epidemiologic data regarding its incidence and the causative organisms. The two leading causes of bacterial pneumonia in childhood are Streptococcus pneumoniae (SP) and Haemophilus influenzae type b (Hib). SP is the major cause of pneumonia beyond the newborn period. In neonates, Group B Streptococcus (GBS) remains a major cause of sepsis and pneumonia despite recent reductions due to targeted perinatal antibiotic prophylaxis. Hib vaccine can prevent pneumonia in developing countries. SP conjugate vaccine prevents X-ray confirmed pneumonia in low incident populations, but protection appears more marginal in high incident populations. Non-vaccine SP serotypes have demonstrated increased carriage and mucosal disease, but not invasive disease following vaccination. GBS vaccines are in the early stages of clinical development as prenatal or antenatal vaccines.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology
01:51Vaccinations